Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...
Read Full NewsPaul Melmeyer, MPP, executive vice president, public policy and advocacy, Muscular Dystrophy Association, explains how adding Duchenne muscular dystrophy to the Recommended Unified Screening Panel reshapes early diagnosis, treatment timing, and family counseling.
The HCPFive: Top News for Healthcare Providers from the Week of 01/11
1.
Q&A: When will individuals be able to receive customized cancer vaccines?
2.
Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.
3.
For the first time in humans, a chemotherapy drug reaches the brain.
4.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
5.
Research has shown that Ga-68 FAPI PET enhances pancreatic cancer detection and staging.
1.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Decoding the Future: Cancer Genomics and Radiomics in Oncology
4.
CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights
5.
Uncovering the Secrets of CA19-9: A Blood Test for Cancer Diagnosis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Understanding the causes of anemia in adults beyond nutritional deficiencies
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge